Joris Zimmermann

Richard Vosser

Chiara Montironi

Jonathan Chang

Michael Nedelcovych

- Molecular Partners reported a strong financial position with **CHF ~105 million** in cash as of **September 30, 2025**, which is expected to fund operations until **2028**.  **[0001745114_2217890:5]** **[0001745114_2217890:7]** **[0001745114_2217890:16]** 
- The company filed an **IND for MP0712**, its 212Pb x DLL3 targeted radiotherapeutic, with a Phase 1 study anticipated to start in **2025** and initial safety data in **H1 2026**.  **[0001745114_2217890:7]** **[0001745114_2217890:10]** **[0001745114_2217890:16]** 
- The strategic collaboration with **Orano Med was expanded to ten 212Pb programs**, and **MP0726** (212Pb x MSLN) was nominated as a lead candidate.  **[0001745114_2217890:7]** **[0001745114_2217890:11]** 
- For **MP0533**, improved response rates were observed with an amended dosing scheme, and initial data from cohort 9 is expected at **ASH 2025**.  **[0001745114_2217890:7]** **[0001745114_2217890:14]** **[0001745114_2217890:16]**

Molecular Partners Reports Strong Financial Position and Pipeline Advancements in Q3 2025

- Molecular Partners announced corporate highlights and unaudited financial results for the third quarter of 2025.  **[1745114_6f4bb8d5d8de43558a87ffff45051a7c_1]** 
- The **IND application for MP0712**, a Radio-DARPin targeting DLL3, has been filed, with Phase 1 initiation expected before year-end 2025, and first patient images from its compassionate care program will be presented in November.  **[1745114_6f4bb8d5d8de43558a87ffff45051a7c_0]** **[1745114_6f4bb8d5d8de43558a87ffff45051a7c_1]** **[1745114_6f4bb8d5d8de43558a87ffff45051a7c_2]** 
- The company maintains a **strong financial position** with **CHF 105 million** in cash and cash equivalents and short-term time deposits as of September 30, 2025, projecting a **cash runway until 2028**.  **[1745114_6f4bb8d5d8de43558a87ffff45051a7c_0]** **[1745114_6f4bb8d5d8de43558a87ffff45051a7c_4]** 
- Updated data from the Phase 1/2a trial of **MP0533** for AML will be presented in December, and a Phase 2 investigator-initiated trial protocol for **MP0317** has been approved.  **[1745114_6f4bb8d5d8de43558a87ffff45051a7c_0]** **[1745114_6f4bb8d5d8de43558a87ffff45051a7c_1]** **[1745114_6f4bb8d5d8de43558a87ffff45051a7c_3]**

Molecular Partners Reports Q3 2025 Results and Clinical Progress

- Molecular Partners reported a **net loss of CHF 11.836 million** for Q3 2025 and **CHF 49.002 million** for the nine months ended September 30, 2025, with basic and diluted net result per share of **(CHF 0.33)** and **(CHF 1.32)**, respectively.  **[1745114_0001745114-25-000037_q32025financialstatements.htm:2]** **[1745114_0001745114-25-000037_q32025financialstatements.htm:1]**  The company maintains a **strong financial position with a cash runway until 2028**, holding **CHF 82.359 million** in cash and cash equivalents as of September 30, 2025.  **[1745114_0001745114-25-000037_prq32025forsecfiling.htm:0]** **[1745114_0001745114-25-000037_q32025financialstatements.htm:1]** 
- An Investigational New Drug (IND) application has been filed for **MP0712**, its lead Radio-DARPin candidate targeting DLL3, with Phase 1 initiation expected before year-end 2025.  **[1745114_0001745114-25-000037_prq32025forsecfiling.htm:0]**  Initial clinical imaging data from a compassionate care program for MP0712 will be presented in November.  **[1745114_0001745114-25-000037_prq32025forsecfiling.htm:0]** 
- Updated data from the Phase 1/2a trial of **MP0533**, a multispecific T cell engager for AML, is scheduled for presentation at ASH in December.  **[1745114_0001745114-25-000037_prq32025forsecfiling.htm:0]**  Additionally, the protocol for a Phase 2 investigator-initiated trial of **MP0317**, a FAP x CD40 agonist, has been approved.  **[1745114_0001745114-25-000037_prq32025forsecfiling.htm:0]** 
- For the nine months ended September 30, 2025, the company recognized **restructuring expenses of CHF 2.733 million** as part of an operational efficiency initiative that included a headcount reduction.  **[1745114_0001745114-25-000037_q32025financialstatements.htm:1]** **[1745114_0001745114-25-000037_q32025financialstatements.htm:7]**

Molecular Partners Reports Q3 2025 Financial Results and Clinical Progress

- Molecular Partners AG reported significant progress in the first half of **2025**, advancing its lead clinical programs **MP0533** and **MP0712**, with an IND filing and Phase 1 trial for **MP0712** anticipated by the end of **2025**.  **[1745114_7f294fc28c85450c85b7c20d996105b6]** 
- The company expanded its strategic partnership with Orano Med to include up to **10** targeted radiotherapy programs.  **[1745114_7f294fc28c85450c85b7c20d996105b6]** 
- Molecular Partners maintains a robust cash position of approximately **CHF 114 million**, securing its operational runway into **2028**, and undertook a workforce reduction to enhance efficiency.  **[1745114_7f294fc28c85450c85b7c20d996105b6]** 
- Martin Steegmaier, Ph.D., was appointed Chief Scientific Officer, though the stock has a neutral analyst rating due to ongoing financial challenges, including negative profitability margins.  **[1745114_7f294fc28c85450c85b7c20d996105b6]**

MOLECULAR PARTNERS (MOLN)